Clinical trial • Neurology

Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis

Clinical trial of Ocrelizumab for Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Relapsing multiple sclerosis | Relapsing-remitting multiple sclerosis | Active secondary progressive multiple sclerosis
Drug Modality
Monoclonal antibody

Key dates

Initial CTIS Submission Date
30-01-2025
First CTIS Authorization Date
01-06-2025

Trial design

Ocrevus (ocrelizumab) — comparator; dose/schedule not specified in the provided record-controlled trial across 22 sites in Croatia, Bulgaria, Poland.

Comparator
Ocrevus (ocrelizumab) — comparator; dose/schedule not specified in the provided record
Target Sample Size
126
Trial Duration For Participant
1423

Eligibility

Recruits 126 Vulnerable population selected; consent/assent handling not specified in the provided record..

Vulnerable Population
Vulnerable population selected; consent/assent handling not specified in the provided record.

Recruitment

Planned Sample Size
126
Recruitment Window Months
46

Geography

Total Number Of Sites
22
Total Number Of Participants
126

Croatia

Earliest CTIS Part Ii Submission Date
25-04-2025
Latest Decision Or Authorization Date
08-12-2025
Processing Time Days
227
Number Of Sites
2
Number Of Participants
7

Sites

Site Name
Opca Bolnica Varazdin
Department Name
Department of Neurology
Principal Investigator Name
Spomenka Kidjemet-Piskac
Principal Investigator Email
spomenka.piskac@obv.hr
Contact Person Name
Spomenka Kidjemet-Piskac
Contact Person Email
spomenka.piskac@obv.hr
Site Name
University Hospital Centre Zagreb
Department Name
Department of Neurology
Principal Investigator Name
Mario Habek
Principal Investigator Email
mario.habek@mef.hr
Contact Person Name
Mario Habek
Contact Person Email
mario.habek@mef.hr

Bulgaria

Earliest CTIS Part Ii Submission Date
09-04-2025
Latest Decision Or Authorization Date
18-11-2025
Processing Time Days
223
Number Of Sites
8
Number Of Participants
29

Sites

Site Name
Acibadem City Clinic Tokuda University Hospital EAD
Department Name
Neurology and Sleep Medicine Clinic
Principal Investigator Name
Ivan Staikov
Principal Investigator Email
ivanstaikov@hotmail.com
Contact Person Name
Ivan Staikov
Contact Person Email
ivanstaikov@hotmail.com
Site Name
Multiprofile Hospital For Active Treatment Medical Complex Sveti Ivan Rilski EOOD
Principal Investigator Name
Kostadin Barzinski
Principal Investigator Email
dr_kburzinski@abv.bg
Contact Person Name
Kostadin Barzinski
Contact Person Email
dr_kburzinski@abv.bg
Site Name
Medical Center Academica 2008 EOOD
Principal Investigator Name
Plamen Tsvetanov
Principal Investigator Email
tzvetanovplamen@hotmail.com
Contact Person Name
Plamen Tsvetanov
Contact Person Email
tzvetanovplamen@hotmail.com
Site Name
Multiprofile Hospital For Active Treatment In Neurology And Psychiatry St. Naum EAD
Department Name
Nervous Diseases Clinic for Locomotor Disorders
Principal Investigator Name
Ivan Milanov
Principal Investigator Email
milanovivan@yahoo.com
Contact Person Name
Ivan Milanov
Contact Person Email
milanovivan@yahoo.com
Site Name
Medical Center Medica 2005 EOOD
Principal Investigator Name
Valentina Ignatova – Valkova
Principal Investigator Email
Valyaig@abv.bg
Contact Person Name
Valentina Ignatova – Valkova
Contact Person Email
Valyaig@abv.bg
Site Name
Diagnostics And Consultation Center Convex Ltd.
Principal Investigator Name
Krasimir Genov
Principal Investigator Email
kr_genov@abv.bg
Contact Person Name
Krasimir Genov
Contact Person Email
kr_genov@abv.bg
Site Name
University Multiprofile Hospital For Active Treatment Saint Georgi EAD
Department Name
Nervous Diseases Clinic
Principal Investigator Name
Penka Atanasova
Principal Investigator Email
prof.penka.atanasova@gmail.com
Contact Person Name
Penka Atanasova
Contact Person Email
prof.penka.atanasova@gmail.com
Site Name
University Multiprofile Hospital For Active Treatment And Emergency Medicine N I Pirogov
Department Name
Nervous Diseases Clinic
Principal Investigator Name
Mariya Dimitrova
Principal Investigator Email
Dr.m.i.dimitrova@gmail.com
Contact Person Name
Mariya Dimitrova
Contact Person Email
Dr.m.i.dimitrova@gmail.com

Poland

Earliest CTIS Part Ii Submission Date
25-04-2025
Latest Decision Or Authorization Date
13-03-2026
Processing Time Days
322
Number Of Sites
12
Number Of Participants
90

Sites

Site Name
Med Polonia Sp. z o.o.
Principal Investigator Name
Karolina Piasecka-Stryczyńska
Principal Investigator Email
kpe@poczta.onet.pl
Contact Person Name
Karolina Piasecka-Stryczyńska
Contact Person Email
kpe@poczta.onet.pl
Site Name
Ma-Lek Clinical Sp. z o.o.
Department Name
Ma-Lek Centrum Terapii SM
Principal Investigator Name
Katarzyna Maciejowska
Principal Investigator Email
k.maciejowska@ctsm.pl
Contact Person Name
Katarzyna Maciejowska
Contact Person Email
k.maciejowska@ctsm.pl
Site Name
Zanamed Medical Clinic Sp. z o.o.
Principal Investigator Name
Małgorzata Kulka
Principal Investigator Email
Malgorzata.kulka@zanmed.pl
Contact Person Name
Małgorzata Kulka
Contact Person Email
Malgorzata.kulka@zanmed.pl
Site Name
Neurocentrum Bydgoszcz Sp. z o.o.
Principal Investigator Name
Paweł Bochniak
Principal Investigator Email
p.bochniak@ncbydgoszcz.pl
Contact Person Name
Paweł Bochniak
Contact Person Email
p.bochniak@ncbydgoszcz.pl
Site Name
Centrum Neurologii Krzysztof Selmaj
Principal Investigator Name
Krzysztof Selmaj
Principal Investigator Email
centrum.neurologii.k.selmaj@gmail.com
Contact Person Name
Krzysztof Selmaj
Site Name
Neuro-Medic Sp. z o.o.
Department Name
Neuro-Medic Poradnia Wielospecjalistyczna
Principal Investigator Name
Janusz Zbrojkiewicz
Principal Investigator Email
jzbrojkiewicz@op.pl
Contact Person Name
Janusz Zbrojkiewicz
Contact Person Email
jzbrojkiewicz@op.pl
Site Name
Niepubliczny Zaklad Opieki Zdrowotnej Neuromed M. I M. Nastaj. sp.p.
Principal Investigator Name
Marcin Nastaj
Principal Investigator Email
marcinnastaj@gmail.com
Contact Person Name
Marcin Nastaj
Contact Person Email
marcinnastaj@gmail.com
Site Name
Samodzielny Publiczny Szpital Kliniczny Nr 1 Im.Prof.Stanislawa Szyszko Slaskiego Uniwersytetu Medycznego W Katowicach
Department Name
Oddział Neurologiczny
Principal Investigator Name
Monika Adamczyk-Sowa
Principal Investigator Email
neurozab@sum.edu.pl
Contact Person Name
Monika Adamczyk-Sowa
Contact Person Email
neurozab@sum.edu.pl
Site Name
Euromedis Sp. z o.o.
Principal Investigator Name
Marcin Ratajczak
Principal Investigator Email
marcin.ratajczak@euromedis.pl
Contact Person Name
Marcin Ratajczak
Contact Person Email
marcin.ratajczak@euromedis.pl
Site Name
Ilkowski I Partnerzy sp.p. Lekarzy
Department Name
NZOZ Neuro-Kard Ilkowski i Partnerzy Spółka Partnerska Lekarzy
Principal Investigator Name
Jan Ilkowski
Principal Investigator Email
jan.ilkowski@neurokard.pl
Contact Person Name
Jan Ilkowski
Contact Person Email
jan.ilkowski@neurokard.pl
Site Name
Centrum Medyczne Neuroprotect
Department Name
Centrum Medyczne NeuroProtect
Principal Investigator Name
Anna Karlińska
Principal Investigator Email
anna.karlinska@neuroprotect.pl
Contact Person Name
Anna Karlińska
Contact Person Email
anna.karlinska@neuroprotect.pl
Site Name
Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o.
Principal Investigator Name
Agata Kłósek
Principal Investigator Email
klosek@twojaprzychodnia.com
Contact Person Name
Agata Kłósek
Contact Person Email
klosek@twojaprzychodnia.com

Sponsor

Primary sponsor

Full Name
H e x a l AG
Organisation Type
Pharmaceutical company
Country Of Registered Address
Germany

Investigational products

Investigational Product Name
CYB704
Active Substance
Ocrelizumab
Modality
Monoclonal antibody
Routes Of Administration
Intravenous infusion
Route
Intravenous
Authorisation Status
Investigational (proposed biosimilar)
Investigational Product Name
Ocrevus (ocrelizumab)
Active Substance
Ocrelizumab
Modality
Monoclonal antibody
Routes Of Administration
Intravenous infusion
Route
Intravenous
Authorisation Status
Authorised (approved product)

Related trials

Other published trials that may interest you.